Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04674969 · ClinicalTrials.gov registry record
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
A clinical trial of Peripheral Vascular Diseases, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 20
- Study locations
NCT04674969 is a study of Peripheral Vascular Diseases that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 5,000 participants, above the 234-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (2037% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04674969, a study of Peripheral Vascular Diseases, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Conditions Studied
Interventions
- DEVICE Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
Study Locations (20)
California
- PIH Health Good Samaritan Hospital - Los Angeles
- Cedars - Sinai Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Sutter Medical Center, Sacramento - Sacramento
- Adventist Health St Helena Hospital - St. Helena
Louisiana
- CIS Clinical Research Corporation - Houma
- Ochsner Clinic Foundation - Kenner
- Cardiovascular Institute of the South - Lafayette
Florida
- Palm Beach Heart & Vascular, LLC - Boynton Beach
- Tallahassee Memorial Hospital - Tallahassee
Georgia
- Emory University Hospital - Atlanta
- South Georgia Medical Center - Valdosta
Illinois
- Rush University - Chicago
- St. John's Hospital/ Prairie Education and Research Cooperative - Springfield
Indiana
- St. Joseph Hospital/Dupont Hospital - Fort Wayne
- Ascension St. Vincent's Hospital - Indianapolis
Arkansas
- St. Bernard's Medical Center - Jonesboro
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2028-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04674969
The ClinicalTrials.gov registry entry for NCT04674969 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 234-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (2037% higher). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Vascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. is the first listed.
NCT04674969 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Louisiana, Florida.
Frequently Asked Questions
What is clinical trial NCT04674969 about?
NCT04674969 is a clinical study titled "Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature". The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices f...
What is the current status of trial NCT04674969?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2021-03-29. Estimated completion is 2028-01.
What conditions does trial NCT04674969 study?
This clinical trial studies the following conditions: Peripheral Vascular Diseases.
What interventions are being tested in trial NCT04674969?
The interventions under investigation include: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. (DEVICE).
Who is sponsoring clinical trial NCT04674969?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04674969 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Vascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
RECRUITING · Phase 1
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
-
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
RECRUITING · Early Phase 1
-
MRI Guided Management of Occlusive Peripheral Arterial Disease
RECRUITING
-
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2
RECRUITING · NA
-
Fisetin to Reduce Senescence and Mobility Impairment in PAD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.